Morphine
1Provenance card
the boundary, as counts
Sources
4028 with DOI
8 strong · 29 moderate · 3 weak
Compilations
12026-04-27T23:15:44.169Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
47last ruled 2026-06-04
1 awaiting a ruling
Issued documents
42026-10-19T20:33:10.631Z
notice · info card · emergency
Searches
170 with no results
queries and counts on the build
Claims checked
8667 supported
67 supported · 19 not
Correspondence
0received
consent field ships in Phase 4
Edges
288
derivations recorded for this entity
Complete over 40 sources, 1 compilation, and 47 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/morphine/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued info_card
- 2026-09-24srcOpioids for cancer pain – an overview of Cochrane reviews
- 2026-09-24srcEmerging Insights into Mu Opioid Pharmacology
- 2026-09-24srcPharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole 'nitazene' synthetic opioid
- 2026-09-24srcSerotonin syndrome and pain medication: What is relevant for practice?
- 2026-09-24srcOpioids for the management of dyspnea in cancer patients: a systematic review and meta-analysis
- 2026-09-24srcAffinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors
- 2026-09-24srcThe Chemical History of Morphine: An 8000-year Journey, from Resin to de-novo Synthesis
- 2026-09-24srcRemifentanil produces cross-desensitization and tolerance with morphine on the mu-opioid receptor
- 2026-09-24srcPharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace
- 2026-09-24srcMorphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial
- 2026-09-24srcDARK Classics in Chemical Neuroscience: Morphine
- 2026-09-24srcThe regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants
- 2026-09-24srcCrystal structure of the µ-opioid receptor bound to a morphinan antagonist
- 2026-09-24srcStructural insights into µ-opioid receptor activation
- 2026-09-24srcOpioid-induced Hyperalgesia
- 2026-09-24srcOpioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study
- 2026-09-24srcActivation of JNK pathway in spinal astrocytes contributes to acute ultra-low-dose morphine thermal hyperalgesia
- 2026-09-24srcFentanyl depression of respiration: Comparison with heroin and morphine
- 2026-09-24srcEfficacy of fentanyl buccal tablet and morphine for exertional dyspnoea in patients with cancer: a double-blind, placebo-controlled, randomised clinical trial
- 2026-09-24srcEndogenous and Exogenous Opioids in Pain
- 2026-09-24srcA systematic review of combination step III opioid therapy in cancer pain: an EPCRC opioid guideline project
- 2026-09-24srcChanges in the development of opioid tolerance on re-exposure among people who use heroin: A qualitative study
- 2026-09-24srcCDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.
- 2026-09-24srcOpioids for the Management of Dyspnea in Cancer Patients: Evidence of the Last 15 Years--A Systematic Review
- 2026-09-24srcThe Influence of Topiramate on Morphine Dependence in Mice
- 2026-09-24srcMorphinan Alkaloids and Their Transformations: A Historical Perspective of a Century of Opioid Research in Hungary
- 2026-09-24srcCannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions
- 2026-09-24srcAtypical opioids and their effect on respiratory drive
- 2026-09-24srcHeroin overdose: causes and consequences
- 2026-09-24srcDoes the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?
- 2026-09-24srcRole of P-glycoprotein in the intestinal absorption and clinical effects of morphine
- 2026-09-24srcReversal of morphine, methadone and heroin induced effects in mice by naloxone methiodide
- 2026-09-24srcClinical pharmacokinetics of morphine
- 2026-09-24srcHigh-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment
- 2026-09-24srcEvaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects
- 2026-09-24srcChronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma
- 2026-09-24srcMorphine: US DEA Schedule II, UK Class A/Schedule 2, Australia Schedule 8, Canada Schedule I, UN Schedule I (Single Convention on Narcotic Drugs)
- 2026-09-24srcMorphine physical properties: CAS 57-27-2, melting point 255°C, sparingly soluble in water (free base)
- 2026-09-24srcMorphine μ opioid receptor binding data: Ki (human MOR) = 1.0 nM (pKi 9.0)
- 2026-09-24srcMorphine (PubChem CID 5288826)
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-07-03proposaldependence · taper
- 2026-06-04proposal44 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-04-27revisionRevision 1
- 2026-04-27genGeneration — pipeline-v5 · with 2 morepipeline-v5
- 2026-04-27rungeneration run
The same entries, as forms: six forms.